Lauren Gratian, MD
Endocrinology, Diabetes & Metabolism · Wilmington, NCNPI 1609019090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,537 of the $34,132 with a category attached, or 80.7%. Recordati_rare_diseases_inc. accounts for 80.0% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $15,844, 3.0 times the $5,225 reported in 2021.
Across 227 payments — averaging $150.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recordati_rare_diseases_inc.$27K
- Chiesi USA, Inc.$3K
- Lilly USA, LLC$656
- Novo Nordisk$341
- Corcept Therapeutics$332
- Abbott$323
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$27,53781%
- Travel & lodging$2,4407%
- Food & beverage$4,11212%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recordati_rare_diseases_inc. | 23 | $27,303 |
| Chiesi USA, Inc. | 5 | $3,029 |
| Lilly USA, LLC | 35 | $656 |
| Novo Nordisk | 18 | $341 |
| Corcept Therapeutics | 11 | $332 |
| Abbott | 25 | $323 |
| Boehringer Ingelheim | 12 | $271 |
| Amgen | 21 | $271 |
| Sanofi-aventis U.S. LLC | 12 | $263 |
| IBSA Pharma Inc. | 12 | $233 |
| Xeris Pharmaceuticals, Inc. | 7 | $136 |
| Tandem Diabetes Care, Inc. | 6 | $118 |
| Bayer | 5 | $111 |
| Mannkind Corporation | 3 | $101 |
| Insulet Corporation | 4 | $94 |
| Ascendis Pharma Endocrinology Inc | 4 | $92 |
| Antares Pharma, Inc. | 4 | $91 |
| Radius Health, Inc. | 4 | $78 |
| Amneal Pharmaceuticals LLC | 4 | $67 |
| Pfizer | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| AstraZeneca | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,132 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $214,701 |
| MounjaroTirzepatide | 150 | $175,644 |
| JardianceEmpagliflozin | 85 | $82,924 |
| TrulicityDulaglutide | 53 | $68,952 |
| ForteoTeriparatide | 12 | $52,197 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $42,023 |
| JanuviaSitagliptin Phosphate | 44 | $30,943 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $26,293 |
| FarxigaDapagliflozin Propanediol | 32 | $25,909 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $20,473 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $17,649 |
| TradjentaLinagliptin | 26 | $16,145 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $13,541 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $9,090 |
| Novolog FlexpenInsulin Aspart | 29 | $7,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $656 | $296,793215 claims |
| Novo NordiskOzempic | $341 | $214,701190 claims |
| Boehringer IngelheimJardiance, Tradjenta | $271 | $99,069111 claims |
| AstraZenecaFarxiga | $38 | $25,90932 claims |
| AbbVieSynthroid | $13 | $3,97148 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $67 | $1,803200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Wilmington
- Michael FavoritoWilmington$723K
- John ParkerWilmington$225K
- Seth BraunsteinWilmington$134K
- Sean McCalmonWilmington$10K
- Michael McGarrityWilmington$9K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.